Vik Khullar

Rufus Cartwright3
Kari A.O. Tikkinen2
Altaf Mangera2
Anna C. Kirby2
Prabhakar Rajan2
3Rufus Cartwright
2Kari A.O. Tikkinen
2Altaf Mangera
2Anna C. Kirby
2Prabhakar Rajan
Learn More
The levator ani is the main muscular support of the pelvic floor organs and damage caused by childbirth can affect its function. The full functionality of this muscle group is still unknown but it is essential for effective surgical planning. To elucidate its functional significance, a physical-based statistical shape model was built from the levator ani(More)
OBJECTIVE Family studies and twin studies demonstrate that lower urinary tract symptoms and pelvic organ prolapse are heritable. This review aimed to identify genetic polymorphisms tested for an association with lower urinary tract symptoms or prolapse, and to assess the strength, consistency, and risk of bias among reported associations. STUDY DESIGN(More)
PURPOSE Long-term persistence with pharmacotherapy for overactive bladder (OAB) requires a drug with an early onset of action and good efficacy and tolerability profile. Although antimuscarinics improve OAB symptoms within 1-2 weeks of initiating treatment, adherence after 3 months is relatively poor due to bothersome side effects (e.g., dry mouth and(More)
  • Rufus Cartwright, Altaf Mangera, Kari A.O. Tikkinen, Prabhakar Rajan, Jori Pesonen, Anna C. Kirby +9 others
  • 2014
CONTEXT Although family studies have shown that male lower urinary tract symptoms (LUTS) are highly heritable, no systematic review exists of genetic polymorphisms tested for association with LUTS. OBJECTIVE To systematically review and meta-analyze studies assessing candidate polymorphisms/genes tested for an association with LUTS, and to assess the(More)
Overactive bladder is a common condition that significantly impacts overall quality of life. Antimuscarinics are the current main pharmacological option for treatment; however, many patients fail to adhere to therapy due to troublesome side effects. Mirabegron is a new beta-3 adrenoreceptor agonist which causes detrusor smooth muscle relaxation and has been(More)
BACKGROUND Fesoterodine is an antimuscarinic for the treatment of overactive bladder, a syndrome of urgency, with or without urgency urinary incontinence (UUI), usually with increased daytime frequency and nocturia. Our objective was to develop predictive models to describe the dose response of fesoterodine. METHODS Data from subjects enrolled in(More)
BACKGROUND Bladder pain syndrome (BPS) pathology is poorly understood. Treatment strategies are empirical, with limited efficacy, and affected patients have diminished quality of life. OBJECTIVE We examined the hypothesis that inflammatory mediators within the bladder contribute to BPS pathology. DESIGN, SETTING, AND PARTICIPANTS Fifteen women with BPS(More)
  • 1